150
Participants
Start Date
November 19, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2028
Alisertib
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Endocrine therapy
"Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter"
RECRUITING
Hospital San Pedro de Alcántara, Cáceres
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
University of Pittsburgh (UPMC), Pittsburgh
RECRUITING
Hospital San Cecilio, Granada
RECRUITING
Alliance Cancer Specialists, Horsham
RECRUITING
University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
RECRUITING
Hospital Universitario Juan Ramon Jimenez, Huelva
RECRUITING
Hospital Universitario de Jaén, Jaén
RECRUITING
Virginia Cancer Institute, Richmond
RECRUITING
Hospital Universitario Arnau de Vilanova, Lleida
RECRUITING
UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Hospital Universitario Fundación Jiménez Díaz, Madrid
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Mayo Clinic Florida, Jacksonville
RECRUITING
Cancer Specialists of North Florida, Jacksonville
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Alabama Oncology, Birmingham
RECRUITING
Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
RECRUITING
Hospital Universitario Virgen del Rocío, Seville
RECRUITING
The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
RECRUITING
Taylor Cancer Research Center, Maumee
RECRUITING
Fundación Instituto Valenciano de Oncología (IVO), Valencia
RECRUITING
Hospital Clínico Universitario de Valencia, Valencia
RECRUITING
Hospital Universitario de Basurto, Bilbao
RECRUITING
Hospital Universitario de Cruces, Barakaldo
RECRUITING
University of Minnesota, Masonic Cancer Center, Minneapolis
RECRUITING
Mayo Clinic, Rochester
RECRUITING
University of Illinois Cancer Center, Chicago
RECRUITING
The University of Chicago, Chicago
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Saint Luke's Cancer Institute, Kansas City
RECRUITING
Oncology Hematology Associates, Springfield
RECRUITING
Texas Oncology, Dallas
RECRUITING
University of Colorado School of Medicine, Aurora
RECRUITING
Mayo Clinic Hospital, Phoenix
RECRUITING
Cancer Care Specialists, Reno
RECRUITING
LA Cancer Network, Los Angeles
RECRUITING
UCLA Department of Medicine - Hematology/Oncology, Los Angeles
RECRUITING
Beverly Hills Cancer Center, Beverly Hills
RECRUITING
City of Hope at Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
MemorialCare Orange Coast Medical Center, Fountain Valley
RECRUITING
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Yale University, Yale Cancer Center, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa), Lisbon
RECRUITING
Fundação Champalimaud, Lisbon
RECRUITING
Hospital CUF Descobertas, Lisbon
RECRUITING
Instituto Português Oncologia Do Porto, Porto
RECRUITING
Hospital General Universitario Dr. Balmis, Alicante
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
RECRUITING
Hospital Clínico de Barcelona, Barcelona
Puma Biotechnology, Inc.
INDUSTRY